Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Structure Elucidation, Signaling Mechanism and Structure-Based Lead Design of the Human Cannabinoid Receptor 2 (CB2)

Xing, Changrui (2020) Structure Elucidation, Signaling Mechanism and Structure-Based Lead Design of the Human Cannabinoid Receptor 2 (CB2). Doctoral Dissertation, University of Pittsburgh. (Unpublished)

[img] PDF
Restricted to University of Pittsburgh users only until 3 August 2022.

Download (4MB) | Request a Copy

Abstract

Cannabinoid receptor 2 (CB2) has an important role in mediating immune signal transduction and is an attractive therapeutic target for chronic neuropain, osteoporosis, autoimmune diseases, and tumors of immune origin. Unlike CB1, which is expressed in the central nervous system (CNS), CB2 is primarily expressed in cells of the immune system and its selective modulation will not produce psychoactive effects. This feature has attracted great interest in CB2, particularly since the anti-obesity drug Rimonabant (CB1 antagonist) was withdrawn from the European market due to depression side effects.
Despite research efforts to date, the CB2 active-state structure, activation mechanism, and allosteric binding features remain elusive, representing a significant hindrance in the development of novel CB2 agonist and allosteric modulators. Thus, in this study, we first unveiled the cryo-EM structure of CB2-Gi signaling complex to gain an unprecedented understanding of the structural and functional mechanisms inherent to CB2 using high-end biophysical and biochemical approaches with purified functional CB2. Next, we developed and applied an innovative residual energy calculation algorithm to aid in the design of a pair of selective CB2 agonist and inverse agonist in order to validate our putative mechanism of receptor activation involving the structural arrangement of critical residues. Then, we investigated the binding features of selective CB2 agonists, as well as the CB2 biased ligand and CB2 positive allosteric modulators (PAMs) and negative allosteric modulators (NAMs).
Collectively, the results from this study will provide insightful information to facilitate structure-based design and discovery of high-affinity and/or high-selectivity CB2 ligands that can be developed as CB2-targeting therapeutic agents.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: University of Pittsburgh ETD
Status: Unpublished
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Xing, Changruichx23@pitt.educhx23
ETD Committee:
TitleMemberEmail AddressPitt UsernameORCID
Committee ChairXie, Xiangqunsean.xie@pitt.edu
Committee MemberZhang, Chengchengzh@pitt.edu
Committee MemberRomero, Guillermoggr@pitt.edu
Committee MemberFeng, Zhiweizhf11@pitt.edu
Committee MemberMcGuire, Terencetfm1@pitt.edu
Committee MemberWang, Junmeijunmei.wang@pitt.edu
Date: 3 August 2020
Date Type: Publication
Defense Date: 14 July 2020
Approval Date: 3 August 2020
Submission Date: 31 July 2020
Access Restriction: 2 year -- Restrict access to University of Pittsburgh for a period of 2 years.
Number of Pages: 136
Institution: University of Pittsburgh
Schools and Programs: School of Pharmacy > Pharmaceutical Sciences
Degree: PhD - Doctor of Philosophy
Thesis Type: Doctoral Dissertation
Refereed: Yes
Uncontrolled Keywords: 3D Structure of Cannabinoid Receptor CB2; Activation Mechanisms of CB2 and CB1; Agonist-bound CB2- Gi Signaling Complex; CB2 Agonist; CB2 Coupling Specificity for Gi; CB2 Drug Discovery; CB2 Inverse Agonist; Cryo-EM structure; Gi Coupling Versatility; Residual Energy Contribution; CB2 biased ligand; CB2 allosteric modulators
Date Deposited: 03 Aug 2020 13:47
Last Modified: 03 Aug 2020 13:47
URI: http://d-scholarship.pitt.edu/id/eprint/39496

Metrics

Monthly Views for the past 3 years

Plum Analytics


Actions (login required)

View Item View Item